Daptomycin Activity Tested Against Linezolid-Nonsusceptible Gram-Positive Clinical Isolates

Daptomycin Activity Tested Against Linezolid-Nonsusceptible Gram-Positive Clinical Isolates

Author Mendes, Rodrigo E. Google Scholar
Jones, Ronald N. Google Scholar
Deshpande, Lalitagauri M. Google Scholar
Ross, James E. Google Scholar
Sader, Helio S. Autor UNIFESP Google Scholar
Institution JMI Labs
Tufts Univ
Universidade Federal de São Paulo (UNIFESP)
Abstract Staphylococcus aureus, coagulase-negative staphylococci, and Enterococcus spp. represent the most frequently recovered organisms from bloodstream infections. As a treatment option, daptomycin has been recently approved for the treatment of S. aureus bacteremia and right-sided endocarditis. We evaluated the spectrum of activity and potency of daptomycin and other antibiotics against 142 linezolid-nonsusceptible clinical strains. the isolates were tested for susceptibility by reference broth microdilution methods utilizing physiologic free calcium ions levels (50 mg/L) when testing daptomycin. Staphylococcus spp. and Enterococcus spp. were selected and screened for 23S rRNA, L4 and L22 mutations, and the cfr gene. Daptomycin was potent against all linezolid-nonsusceptible staphylococci (minimal inhibitory concentrations [MIC](90), 0.5 mu g/ml) and enterococci (MIC90, 1 mu g/ml) isolates at the respective breakpoints of <= 1 mu g/ml and <= 4 mu g/ml. the majority of the isolates (84.5%) showed ribosomal target-site alterations, mainly G2576T, and five isolates (two S. aureus and three Staphylococcus epidermidis) had the mobile cfr element. in conclusion, daptomycin was the most active agent tested against this collection of gram-positive clinical organisms and ribosomal target mutations comprised the main resistance mechanism against linezolid.
Language English
Sponsor AB BIODISK
Abbott
API
Arpida
Astellas
AstraZeneca
Avexa
Bayer
bioMerieux
Cadence
Cempra
Cerexa
Cornerstone
Cubist
Daiichi
Elan
Elanco
Enanta
GlaxoSmithKline
Johnson & Johnson (Ortho McNeil)
Merck
Novartis
Optimer
Ordway
Pacific Beach
Pfizer
Protez
Replidyne
Schering-Plough
Sequoia
Shionogi
Theravance
TREK Diagnostics
ViroPharma
Wyeth
Cubist Pharmaceuticals
Date 2009-12-01
Published in Microbial Drug Resistance. New Rochelle: Mary Ann Liebert, Inc, v. 15, n. 4, p. 245-249, 2009.
ISSN 1076-6294 (Sherpa/Romeo, impact factor)
Publisher Mary Ann Liebert, Inc
Extent 245-249
Origin http://dx.doi.org/10.1089/mdr.2009.0045
Access rights Closed access
Type Article
Web of Science ID WOS:000271142800002
URI http://repositorio.unifesp.br/handle/11600/32000

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account